The stock of Atea Pharmaceuticals Inc. (AVIR) has seen a 32.17% increase in the past week, with a 43.35% gain in the past month, and a 29.29% flourish in the past quarter. The volatility ratio for the week is 7.09%, and the volatility levels for the past 30 days are at 4.88% for AVIR. The simple moving average for the last 20 days is 31.11% for AVIR’s stock, with a simple moving average of -3.01% for the last 200 days.
Is It Worth Investing in Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Right Now?
Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 1 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for Atea Pharmaceuticals Inc. (AVIR) is $5.33, which is -$0.74 below the current market price. The public float for AVIR is 75.70M, and currently, short sellers hold a 2.25% ratio of that floaft. The average trading volume of AVIR on May 25, 2023 was 751.36K shares.
AVIR) stock’s latest price update
Atea Pharmaceuticals Inc. (NASDAQ: AVIR)’s stock price has gone decline by -1.35 in comparison to its previous close of 4.81, however, the company has experienced a 32.17% increase in its stock price over the last five trading days. The Wall Street Journal reported on 04/03/22 that Biotech Stocks, Once Booming, Enter Bear Territory
AVIR Trading at 37.48% from the 50-Day Moving Average
After a stumble in the market that brought AVIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.53% of loss for the given period.
Volatility was left at 4.88%, however, over the last 30 days, the volatility rate increased by 7.09%, as shares surge +43.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.00% upper at present.
During the last 5 trading sessions, AVIR rose by +32.17%, which changed the moving average for the period of 200-days by -44.04% in comparison to the 20-day moving average, which settled at $3.69. In addition, Atea Pharmaceuticals Inc. saw -1.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVIR starting from BERGER FRANKLIN M, who sale 16,166 shares at the price of $5.16 back on Nov 14. After this action, BERGER FRANKLIN M now owns 778,353 shares of Atea Pharmaceuticals Inc., valued at $83,352 using the latest closing price.
BERGER FRANKLIN M, the Director of Atea Pharmaceuticals Inc., sale 25,500 shares at $5.15 during a trade that took place back on Nov 11, which means that BERGER FRANKLIN M is holding 794,519 shares at $131,333 based on the most recent closing price.
Stock Fundamentals for AVIR
The total capital return value is set at -19.30, while invested capital returns managed to touch -17.13. Equity return is now at value -16.90, with -16.30 for asset returns.
Based on Atea Pharmaceuticals Inc. (AVIR), the company’s capital structure generated 0.49 points at debt to equity in total, while total debt to capital is 0.49. Total debt to assets is 0.47, with long-term debt to equity ratio resting at 0.38. Finally, the long-term debt to capital ratio is 0.37.
The liquidity ratio also appears to be rather interesting for investors as it stands at 35.77.
Conclusion
In a nutshell, Atea Pharmaceuticals Inc. (AVIR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
